Supernus Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Supernus Pharmaceuticals, Inc. (SUPN) develops and commercializes products for the treatment of central nervous system (CNS) disorders, epilepsy, and other neurological conditions. The company offers a portfolio of branded products including Trokendi XR (extended-release topiramate) for epilepsy and migraine prevention; Oxtellar XR (extended-release oxcarbazepine) for partial seizure treatment; Qudexy XR (extended-release topiramate) for epilepsy and migraine prophylaxis; and SPN-817, an investigational product in clinical development for treatment-resistant epilepsy. Additional pipeline candidates include SPN-830 (apomorphine infusion device for Parkinson's disease motor fluctuations) and SPN-820 (viloxazine extended-release for major depressive disorder), with research focused on novel formulations and delivery systems for CNS therapeutics. Supernus operates primarily in the United States, with headquarters in Rockville, Maryland, where it was founded in 2005. In recent developments, Supernus strengthened its epilepsy portfolio through the 2024 FDA approval and launch of a generic equivalent to Epidiolex (cannabidiol oral solution), expanding access to treatments for rare epilepsy syndromes such as Lennox-Gastaut syndrome and Dravet syndrome. The company also advanced its pipeline with positive topline results from the Phase 3 trial of SPN-817 in mid-2025, supporting a New Drug Application submission planned for late 2025, and initiated a strategic collaboration with a leading device manufacturer for the SPN-830 infusion pump commercialization. No major acquisitions, funding rounds, or reorganizations have been reported in the last two years, allowing focus on organic growth and regulatory milestones in the competitive CNS pharmaceuticals segment targeting neurologists, epileptologists, and pediatric specialists.
Company News
Supernus Pharmaceuticals to Participate in September Investor Conferences
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
Critical Survey: Vectura Group (OTCMKTS:VEGPF) versus Supernus Pharmaceuticals (NASDAQ:SUPN)
Allworth Financial LP Invests $2.36 Million in Supernus Pharmaceuticals, Inc. $SUPN
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.
California State Teachers Retirement System Grows Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders?
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
New Strong Buy Stocks for August 7th
Best Value Stocks to Buy for August 7th
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Why Supernus Pharmaceuticals Stock Topped the Market Today